Alnylam Pharmaceuticals Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
270.19
19.04
(7.58%)
Volume:
1,252,040
52 week range:
144.73 - 304.39
Market Cap:
35.230B
Company Description:
Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.